RPG LIFE SCIENCES LTD

The investor presentation dated September 2, 2026, outlines strategic developments for RPG Life Sciences Limited (RPGLIFE). The API business has been transferred to a new subsidiary, RPGAP, through a slump sale, with 100% ownership by RPGAP. RPGAP has partnered with InvAscent, a pharma-focused private equity firm, with InvAscent acquiring a 40% stake via primary issuance for ~243.33 Cr INR. RPGAP also acquired Actis Generics for ~80 Cr INR, a fully integrated API manufacturer in Vizag, and Raghava Life Sciences via slump sale for ~135 Cr INR, adding manufacturing capacity and R&D capabilities. The presentation highlights RPGAP's strategic focus on API, enhanced product portfolios, and growth through partnerships and acquisitions. Management emphasized operational strengths, including state-of-the-art facilities, R&D initiatives, and long-term customer relationships, alongside financial prudence with zero debt and sufficient liquidity for future growth.

The presentation emphasizes strategic advancements, partnerships, and operational strengths with no mention of challenges or risks.